Real Stock Plays

[fast.money]

$CIHN Due Diligence Highlights:

* CIHN has recently entered into stem cell market that is projected to be a 6.6 billion dollar industry by 2016.

* CIHN has investor interest surging and once the market begins to grasp this company's outstanding potential, we believe that a massive run can develop ad continue.

* CIHN appoints Dr. Leonel Liriano as their Regenerative BioScience Medical Director. This is huge news brining in such a big name surgeon with years of experience. Definitely shows that CIHN is on the right track and making big moves. See what CIHN’s Chairman and CEO, Steven Swank has to say, "I have received stem cells myself 3 years ago and am a true believer in its potential after seeing my health improvements. Dr. Liriano shares our vision of helping to improve quality of life and we could not be more excited to have someone with this extensive experience and knowledge in this field join as our Medical Director."